Skip to main content
SpringerLink
Log in

Platelet Glycoprotein IIb/IIIa Receptor Blockade in Primary Coronary Intervention

  • Chapter
  • First Online:
Primary Angioplasty in Acute Myocardial Infarction

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 791 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brener SJ. Insights into the pathophysiology of ST-elevation myocardial infarction. Am Heart J 2006; 151(6 Suppl): S4–10.

    Article  PubMed  CAS  Google Scholar 

  2. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 14(4): 813–36.

    Article  PubMed  CAS  Google Scholar 

  3. Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Annu Rev Med 1992; 43: 171–80.

    Article  PubMed  CAS  Google Scholar 

  4. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260(20): 11107–14.

    PubMed  CAS  Google Scholar 

  5. Pumphrey CW, Dawes J. Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction. Am J Cardiol 1982; 50(6): 1258–61.

    Article  PubMed  CAS  Google Scholar 

  6. Fuchs J, Weinberger I, Rotenberg Z, Joshua H, Almozlino A, Agmon J. Circulating aggregated platelets in coronary artery disease. Am J Cardiol 1987; 60(7): 534–7.

    Article  PubMed  CAS  Google Scholar 

  7. Hughes A, Daunt S, Vass G, Wickes J. In vivo platelet activation following myocardial infarction and acute coronary ischaemia. Thromb Haemost 1982; 48(2): 133–5.

    PubMed  CAS  Google Scholar 

  8. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77(1): 142–50.

    PubMed  CAS  Google Scholar 

  9. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329(10): 673–82.

    Article  Google Scholar 

  10. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328(10): 673–9.

    Article  PubMed  CAS  Google Scholar 

  11. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361(9351): 13–20.

    Article  PubMed  Google Scholar 

  12. Iwabuchi M, Haruta S, Taguchi A, et al. Intravascular ultrasound findings after successful primary angioplasty for acute myocardial infarction: predictors of abrupt occlusion. J Am Coll Cardiol 1997; 30(6): 1437–44.

    Article  PubMed  CAS  Google Scholar 

  13. Weinberger I, Fuchs J, Davidson E, Rotenberg Z. Circulating aggregated platelets, number of platelets per aggregate, and platelet size during acute myocardial infarction. Am J Cardiol 1992;70(11): 981–3.

    Article  PubMed  CAS  Google Scholar 

  14. Gasperetti CM, Gonias SL, Gimple LW, Powers ER. Platelet activation during coronary angioplasty in humans. Circulation 1993;88(6): 2728–34.

    PubMed  CAS  Google Scholar 

  15. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2(8607): 349–60.

    Google Scholar 

  16. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 1992;19(3): 671–7.

    Article  PubMed  CAS  Google Scholar 

  17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308(6921): 81–106.

    Google Scholar 

  18. Weitz JI, Califf RM, Ginsberg JS, Hirsh J, Theroux P. New antithrombotics. Chest 1995;108(4 Suppl): 471S–85S.

    Article  PubMed  CAS  Google Scholar 

  19. Bates ER, McGillem MJ, Mickelson JK, Pitt B, Mancini GB. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991;84(6): 2463–9.

    PubMed  CAS  Google Scholar 

  20. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997; 95(7): 1755–9.

    PubMed  CAS  Google Scholar 

  21. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77(3): 670–7.

    PubMed  CAS  Google Scholar 

  22. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54(6): 1496–508.

    Article  PubMed  CAS  Google Scholar 

  23. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention. Circulation 1994; 89(6): 2514–8.

    PubMed  CAS  Google Scholar 

  24. Kitazume H, Kubo I, Iwama T. Long-term angiographic prognosis of lesions dilated by coronary angioplasty. Am Heart J 1998; 135(6 Pt 1): 1076–80.

    Article  PubMed  CAS  Google Scholar 

  25. Feld H, Lichstein E, Schachter J, Shani J. Early and late angiographic findings of the “no-reflow” phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992; 123(3): 782–4.

    Article  PubMed  CAS  Google Scholar 

  26. Marzilli M, Gliozheni E, Marraccini P, Fedele S. Primary coronary angioplasty in acute myocardial infarction: clinical correlates of the ‘no reflow’ phenomenon. Int J Cardiol 1998; 65 Suppl 1: S23–8.

    Article  Google Scholar 

  27. Komamura K, Kitakaze M, Nishida K, et al. Progressive decreases in coronary vein flow during reperfusion in acute myocardial infarction: clinical documentation of the no reflow phenomenon after successful thrombolysis. J Am Coll Cardiol 1994; 24(2): 370–7.

    Article  PubMed  CAS  Google Scholar 

  28. Seydoux C, Goy JJ, Davies G. Platelet and neutrophil imaging techniques in the investigation of the response to thrombolytic therapy and the no-reflow phenomenon. Am Heart J 1993; 125(4): 1142–7.

    Article  PubMed  CAS  Google Scholar 

  29. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330(14): 956–61.

    Article  Google Scholar 

  30. Mehta JL, Nichols WW, Mehta P. Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J Am Coll Cardiol 1988; 11(6): 1309–16.

    Article  PubMed  CAS  Google Scholar 

  31. Rawitscher D, Levin TN, Cohen I, Feldman T. Rapid reversal of no-reflow using Abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997; 42(2): 187–90.

    Article  PubMed  CAS  Google Scholar 

  32. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341(26): 1949–56.

    Article  PubMed  CAS  Google Scholar 

  33. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346(13): 957–66.

    Article  PubMed  CAS  Google Scholar 

  34. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996; 77(12): 1045–51.

    Article  PubMed  CAS  Google Scholar 

  35. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349(9063): 1422–8.

    Article  Google Scholar 

  36. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96(5): 1445–53.

    Google Scholar 

  37. Grantham JA, Hasdal D, Kopecky SL, Holmes DR, Jr. Platelet glycoprotein IIb/IIIa receptor inhibition during PTCA for acute MI. J Am Coll Cardiol 1998; 31(Supplement 1): 231A.

    Article  Google Scholar 

  38. van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999; 33(6): 1528–32.

    Article  PubMed  Google Scholar 

  39. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76(1): 142–54.

    PubMed  CAS  Google Scholar 

  40. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328(10): 680–4.

    Article  PubMed  CAS  Google Scholar 

  41. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336(23): 1621–8.

    Article  Google Scholar 

  42. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98(8): 734–41.

    PubMed  CAS  Google Scholar 

  43. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98(24): 2695–701.

    PubMed  CAS  Google Scholar 

  44. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997; 78(1): 730–5.

    PubMed  CAS  Google Scholar 

  45. Gawaz M, Neumann FJ, Dickfeld T, et al. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96(6): 1809–18.

    PubMed  CAS  Google Scholar 

  46. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17(3): 528–35.

    PubMed  CAS  Google Scholar 

  47. Fan ST, Edgington TS. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol 1993; 150(7): 2972–80.

    PubMed  CAS  Google Scholar 

  48. Murphy JF, Bordet JC, Wyler B, et al. The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J 1994; 304 (Pt 2): 537–42.

    PubMed  CAS  Google Scholar 

  49. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344(25): 1895–903.

    Article  PubMed  CAS  Google Scholar 

  50. The ADMIRAL Investigators. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study. Eur Heart J 2005;26(23): 2520–3.

    Article  Google Scholar 

  51. Kaul U, Gupta RK, Haridas KK, et al. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study. Catheter Cardiovasc Interv 2002; 57(4): 497–503.

    Article  PubMed  Google Scholar 

  52. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42(11): 1879–85.

    Article  PubMed  CAS  Google Scholar 

  53. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004; 109(14): 1704–6.

    Article  PubMed  CAS  Google Scholar 

  54. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003; 42(11): 1886–9.

    Article  PubMed  Google Scholar 

  55. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35(4): 915–21.

    Article  PubMed  CAS  Google Scholar 

  56. Gibson CM, Kirtane AJ, Murphy SA, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006; 152(4): 668–75.

    Article  PubMed  CAS  Google Scholar 

  57. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292(3): 362–6.

    Article  PubMed  CAS  Google Scholar 

  58. van't Hof AW, Ernst N, de Boer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004; 25(10): 837–46.

    Article  Google Scholar 

  59. Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107(11): 1497–501.

    Article  PubMed  Google Scholar 

  60. Cutlip DE, Ricciardi MJ, Ling FS, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003; 92(8): 977–80.

    Article  PubMed  CAS  Google Scholar 

  61. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002; 90(5): 533–6.

    Article  PubMed  CAS  Google Scholar 

  62. Arntz H-R, Schroder J, Pels K. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REO-MOBILE-study. Eur Heart J 2003; 24 (abstract suppl): 268.

    Article  Google Scholar 

  63. Gabriel HM, Oliveira J, Silva PCd. Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trial. Eur Heart J 2003; 24 (abstract suppl): 543.

    Article  Google Scholar 

  64. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293(14): 1759–65.

    Article  PubMed  Google Scholar 

  65. Borden WB, Faxon DP. Facilitated percutaneous coronary intervention. J Am Coll Cardiol 2006; 48(6): 1120–8.

    Article  PubMed  Google Scholar 

  66. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357(9272): 1905–14.

    Article  PubMed  CAS  Google Scholar 

  67. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358(9282): 605–13.

    Article  Google Scholar 

  68. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 2004; 147(4): E16.

    Article  PubMed  Google Scholar 

  69. Hanefeld C, Sirtl C, Spiecker M, et al. Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study. Chest 2004; 126(3): 935–41.

    Article  PubMed  CAS  Google Scholar 

  70. Deibele AJ, Kirtane AJ, Pinto DS, et al. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 2006; 22(1): 47–50.

    Article  PubMed  Google Scholar 

  71. Sharma S, Makkar R, Lardizabal J. Intracoronary administration of abciximab during percutaneous coronary interventions: should this be the routine and preferred approach? J Cardiovasc Pharmacol Ther 2006; 11(2): 136–41.

    Article  PubMed  CAS  Google Scholar 

  72. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107(14): 1840–3.

    Article  PubMed  Google Scholar 

  73. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 2004; 61(1): 31–4.

    Article  PubMed  Google Scholar 

  74. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336(24): 1689–96.

    Article  Google Scholar 

  75. Muhlestein JB, Karagounis LA, Treehan S, Anderson JL. “Rescue” utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30(7): 1729–34.

    Article  PubMed  CAS  Google Scholar 

  76. Brener SJ, Ellis SG, DeLuca SA, Topol EJ. Abciximab in coronary angioplasty – comparison of planned and rescue administration. J Invasive Cardiol 1997; 9: 50C.

    Google Scholar 

  77. Kereiakes DJ. Preferential benefit of platelet glycoprotein IIb/IIIa receptor blockade: specific considerations by device and disease state. Am J Cardiol 1998; 81(7A): 49E–54E.

    Article  PubMed  CAS  Google Scholar 

  78. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30(5): 1193–9.

    Article  PubMed  CAS  Google Scholar 

  79. Fischell TA, Carter AJ, Foster MT, et al. Reversal of “no reflow” during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998; 45(4): 360–5.

    Article  PubMed  CAS  Google Scholar 

  80. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112(9): 1284–8.

    Article  PubMed  CAS  Google Scholar 

  81. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352(9122): 87–92.

    Article  Google Scholar 

  82. Koreny M, Riedmuller E, Nikfardjam M, Siostrzonek P, Mullner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA 2004; 291(3): 350–7.

    Article  PubMed  CAS  Google Scholar 

  83. Krause PB, Klein LW. Utility of a percutaneous collagen hemostasis device: to plug or not to plug? J Am Coll Cardiol 1993; 22(5): 1280–2.

    Article  PubMed  CAS  Google Scholar 

  84. Silber S. Rapid hemostasis of arterial puncture sites with collagen in patients undergoing diagnostic and interventional cardiac catheterization. Clin Cardiol 1997; 20(12): 981–92.

    Article  PubMed  CAS  Google Scholar 

  85. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44(3): E1–E211.

    Article  PubMed  Google Scholar 

  86. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47(1): e1–121.

    Article  PubMed  Google Scholar 

  87. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996; 94(4): 629–35.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, NY Methodist Hospital, Brooklyn, NY 11215

    Sorin J. Brener

Authors
  1. Adnan K. Chhatriwalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sorin J. Brener
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sorin J. Brener .

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Humana Press, a part of Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Chhatriwalla, A.K., Brener, S.J. (2009). Platelet Glycoprotein IIb/IIIa Receptor Blockade in Primary Coronary Intervention. In: Tcheng, J. (eds) Primary Angioplasty in Acute Myocardial Infarction. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-60327-497-5_10

    Download citation

    • DOI: https://doi.org/10.1007/978-1-60327-497-5_10

    • Published:

    • Publisher Name: Humana Press

    • Print ISBN: 978-1-60327-496-8

    • Online ISBN: 978-1-60327-497-5

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation